logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Renal cancer: better quality-adjusted survival with pembrolizumab, but higher cost

Price reductions can make the cost of pembrolizumab-axitinib proportional to its clinical value.